Loading the records…
Loading the records…
HR10954, introduced by Rep. Sheri Biggs, would require abortion drugs to carry a 'Do Not Flush' warning label and include a catch kit. The bill is in early stage, referred to the House Energy and Commerce Committee, and does not authorize any funding. No publicly traded company is directly and materially affected, resulting in negligible near-term market impact.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill does not create any new market opportunities or risks for publicly traded companies. The healthcare sector may see minor compliance costs if the bill advances, but these are unlikely to be material for any listed firm. Investors should focus on other legislative signals with clearer financial implications.
HR10954 was introduced on November 5, 2026, and referred to the House Committee on Energy and Commerce. The bill amends the Federal Food, Drug, and Cosmetic Act to require that abortion drugs be deemed misbranded unless they include a 'Do Not Flush' warning label and a catch kit. This is a labeling and packaging requirement that would impose compliance costs on manufacturers of abortion drugs. However, the primary manufacturer of mifepristone (Danco Laboratories) is privately held, and misoprostol is generic with multiple manufacturers. No publicly traded pharmaceutical company derives a significant portion of revenue from these drugs. The bill is at an early legislative stage with only one cosponsor, and its path to enactment is uncertain. Given the lack of direct financial exposure for publicly traded companies, the market impact is minimal. The bill does not authorize any appropriations, so there is no government funding at stake. Investors should monitor committee activity for any amendments that could broaden the bill's scope, but as of now, no tickers are affected.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →